B Cell Vaccine Promotes Anti-glioma Immunity Through Modulating CD8+ T cells

Project: Research project

Project Details

Description

Glioblastoma (GBM) is a deadly brain cancer with a current survival of only 15 months despite standard of care. Immunotherapy, which utilizes the body’s own immune system to target the cancer, is a promising new approach to treating GBM that has shown significant efficacy in many other cancer types. The utilization of B cells as an immunotherapy is a novel approach, and we previously showed our B cell based vaccine (Bvax) can confer a very potent survival benefit in preclinical GBM models. The goal of this study is to investigate the underlying mechanisms of our B cell vaccine to both improve our current vaccine as well as develop novel immunotherapy strategies against GBM.
StatusFinished
Effective start/end date6/1/228/31/22

Funding

  • American Brain Tumor Association (MSSF2200050)

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.